Arvinas

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. 

CEO
Randy Teel
CEORandy Teel
Employees
246
Employees246
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2013
Founded2013
Employees
246
Employees246

ARVN Key Statistics

Market cap
848.76M
Market cap848.76M
Price-Earnings ratio
-10.91
Price-Earnings ratio-10.91
Dividend yield
Dividend yield
Average volume
979.62K
Average volume979.62K
High today
$13.47
High today$13.47
Low today
$12.95
Low today$12.95
Open price
$13.07
Open price$13.07
Volume
850.40K
Volume850.40K
52 Week high
$18.93
52 Week high$18.93
52 Week low
$5.90
52 Week low$5.90

Stock Snapshot

Arvinas(ARVN) stock is priced at $13.27, giving the company a market capitalization of 848.76M. It carries a P/E multiple of -10.91.

On 2026-03-01, Arvinas(ARVN) stock traded between a low of $12.95 and a high of $13.47. Shares are currently priced at $13.27, which is +2.5% above the low and -1.5% below the high.

The Arvinas(ARVN)'s current trading volume is 850.4K, compared to an average daily volume of 979.62K.

During the past year, Arvinas(ARVN) stock moved between $5.90 at its lowest and $18.93 at its peak.

During the past year, Arvinas(ARVN) stock moved between $5.90 at its lowest and $18.93 at its peak.

ARVN News

TipRanks 4d
Top Arvinas Executives Quietly Cash Out in Fresh Wave of Insider Stock Sales

New insider activity at Arvinas Holding Company ( (ARVN) ) has taken place on February 25, 2026. Arvinas Holding Company has seen notable insider activity as t...

TipRanks 5d
Arvinas price target raised to $11 from $9 at Wedbush

Wedbush analyst Robert Driscoll raised the firm’s price target on Arvinas (ARVN) to $11 from $9 and keeps a Neutral rating on the shares following quarterly res...

TipRanks 5d
Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts

TD Cowen analyst Tyler Van Buren has maintained their neutral stance on ARVN stock, giving a Hold rating today. Claim 50% Off TipRanks Premium Unlock hedge fund...

Analyst ratings

56%

of 18 ratings
Buy
55.6%
Hold
38.9%
Sell
5.6%

More ARVN News

Nasdaq 5d
Arvinas Q4 2025 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Arvinas Q4 2025 Earnings Call Transcript

People also own

Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.